Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and several distinguished researchers will be presenting new research and applications at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting February 23-26th.

Quantum-Si, the pioneer in Next-Generation Protein Sequencing (NGPS™) will feature groundbreaking research through one company-led poster and two customer-led posters highlighting the transformative capabilities of NGPS in multi-omics research and drug discovery.

Scientific Posters Highlighting NGPS Innovation

Beyond the genome: Advancing our understanding of the proteome with Next-Generation Protein Sequencing™

  • Presenter: Meredith Carpenter, Ph.D., Head of Scientific Affairs, Quantum-Si
  • Introduces how NGPS offers an integrated understanding of cellular processes by detecting changes at the protein level (such as post-translational modifications, or PTMs) that cannot be captured by genomics data alone.
  • February 25th, Poster 412

Integrating long-read RNAseq and Next-Generation Protein Sequencing™ to explore proteoform variability

  • Presenter: Gloria Sheynkman, Ph.D., Assistant Professor, University of Virginia
  • Demonstrates the integration of long-read RNA sequencing to capture transcript isoforms, combined with the benchtop instrument Platinum™ to produce single-molecule peptide sequencing data.
  • February 25th Poster 476

Identifying Protein Binding Partners at the Bench Using Quantum-Si

  • Presenter: Winston Timp, Ph.D., Associate Professor, BioMedical Engineering and Molecular Biology and Genetics, Johns Hopkins University
  • Demonstrates how NGPS enables direct peptide sequencing to identify protein partners regulated by genomic, epigenomic, or splicing variation, offering a rapid and cost-effective alternative to legacy technologies.
  • February 24th, Poster 465

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® line of instruments enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

Investor Contact Jeff Keyes Chief Financial Officer ir@quantum-si.com Media Contact Katherine Atkinson SVP, Commercial Marketing media@quantum-si.com

Quantum Si (NASDAQ:QSI)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more Quantum Si Charts.
Quantum Si (NASDAQ:QSI)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more Quantum Si Charts.